Company intelligence / Profile preview
Nemucore Medical Innovations
Wellesley, Massachusetts, United Statesnemucore.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Nemucore's lead program NMI-900, an Aurora kinase inhibitor for AML, has shown promise in preclinical studies with high Aurora B kinase correlation to AML and positive signals in animal models.[2] The company pairs this therapeutic with a companion diagnostic using RNA measurement (rather than DNA) to identify patients who will respond to treatment.[6]
- Therapeutic areas
- OncologyHematology
- Modalities
- Small moleculeNanoparticle
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Medical Prognosis Institute (MPI) - partnership for companion diagnostic development using MPI's Drug Response Predictor platform
Beyond the preview
Go deeper on Nemucore Medical Innovations.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nemucore Medical Innovations.